Palumbo Wealth Management LLC Takes $221,000 Position in Sana Biotechnology, Inc. $SANA

Key Points

• Palumbo Wealth Management LLC has acquired a new position in Sana Biotechnology, purchasing 81,093 shares valued at approximately $221,000 during the second quarter.
• Sana Biotechnology's stock is currently valued at $3.39, with a market capitalization of $806.18 million, and it reported a quarterly EPS of ($0.16), beating analyst estimates.
• Analysts are generally positive on Sana Biotechnology, with seven analysts rating the stock as a "Buy" and a consensus target price of $7.50.

Palumbo Wealth Management LLC acquired a new position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 81,093 shares of the company's stock, valued at approximately $221,000.

A number of other institutional investors and hedge funds also recently modified their holdings of SANA. Millennium Management LLC raised its position in Sana Biotechnology by 604.8% in the fourth quarter. Millennium Management LLC now owns 728,901 shares of the company's stock worth $1,188,000 after acquiring an additional 625,481 shares during the period. Invesco Ltd. grew its position in shares of Sana Biotechnology by 241.5% during the 1st quarter. Invesco Ltd. now owns 165,646 shares of the company's stock valued at $278,000 after purchasing an additional 117,144 shares in the last quarter. Two Sigma Advisers LP increased its stake in Sana Biotechnology by 677.0% in the 4th quarter. Two Sigma Advisers LP now owns 209,000 shares of the company's stock worth $341,000 after acquiring an additional 182,100 shares during the last quarter. SCS Capital Management LLC purchased a new stake in Sana Biotechnology in the first quarter valued at approximately $137,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Sana Biotechnology by 10.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 279,282 shares of the company's stock worth $455,000 after acquiring an additional 25,383 shares during the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.

Sana Biotechnology Stock Down 0.6%

Sana Biotechnology stock opened at $3.39 on Friday. The firm has a market capitalization of $806.18 million, a price-to-earnings ratio of -3.20 and a beta of 1.88. Sana Biotechnology, Inc. has a 52-week low of $1.26 and a 52-week high of $7.30. The company has a fifty day simple moving average of $3.57 and a 200-day simple moving average of $2.75.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.04. On average, research analysts anticipate that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on SANA shares. JMP Securities reaffirmed a "market outperform" rating and issued a $5.00 target price on shares of Sana Biotechnology in a research note on Tuesday, June 24th. Morgan Stanley started coverage on Sana Biotechnology in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $12.00 price target for the company. Finally, Wedbush started coverage on Sana Biotechnology in a research report on Wednesday. They set an "outperform" rating and a $5.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $7.50.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.

Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.